🎁 Black Friday: 50% off Unlimited and 30% off Pro annual plans
Ultragenyx Pharmaceutical Inc. (RARE)
NASDAQ: RARE · Real-Time Price · USD
16.48
-0.74 (-4.30%)
At close: Nov 20, 2026, 4:00 PM EST
16.50
+0.02 (0.12%)
After-hours: Nov 20, 2026, 7:31 PM EST

Ultragenyx Pharmaceutical Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
-524-575-569-607-707.42-454.03
Depreciation & Amortization
3435362618.2213.24
Asset Writedown & Restructuring Costs
----75.03-
Loss (Gain) From Sale of Investments
-1-4-13-132248.67
Stock-Based Compensation
135153158135130.38104.95
Other Operating Activities
-47-52-40-21.0911.71
Change in Accounts Receivable
-54-31-34-23-12.07-5.43
Change in Inventory
-8-6-11-7-9.7-3.12
Change in Accounts Payable
292447-179.8532.31
Change in Unearned Revenue
------57.49
Change in Other Net Operating Assets
-1-1012153.8-29.51
Operating Cash Flow
-437-466-414-475-380.47-338.7
Operating Cash Flow Growth
------

Investing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Capital Expenditures
-5-6-7-44-116.12-73.09
Cash Acquisitions
-----75.03-
Sale (Purchase) of Intangibles
-5-15-13-3-30-
Investment in Securities
-82584221-69.66-121.34
Other Investing Activities
-1-1-2-6-0.84-0.94
Investing Cash Flow
-19236-18168-291.65-195.37

Financing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Issuance of Common Stock
158639238710.81119.04
Other Financing Activities
39239271490.4-0.49
Financing Cash Flow
407478399388501.21118.55

Net Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Foreign Exchange Rate Adjustments
-24-2--1.08-1.19
Net Cash Flow
-51252-3581-171.98-416.71

Free Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
-442-472-421-519-496.59-411.79
Free Cash Flow Growth
------
Free Cash Flow Margin
-60.55%-70.13%-75.18%-119.59%-136.68%-117.18%
Free Cash Flow Per Share
-4.37-4.79-4.65-7.06-7.10-6.07
Levered Free Cash Flow
-179.38-251.13-207-312.54-370.58-244.82
Unlevered Free Cash Flow
-127.5-212.38-167.63-271.29-343.7-226.43

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash Income Tax Paid
44----
Change in Working Capital
-34-2314-1660.24-63.24
SEC Filings: 10-K · 10-Q